Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.77 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044296 | 0.88 | MAPT (0.69) | MAPTHCAR3KMT2AMEN1HPGD | |
| SCHEMBL6043895 | 0.88 | MAPT (0.72) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL27298735 | 0.81 | MAPT (0.72) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL6043949 | 0.81 | HCAR3 (1.00) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL19278151 | 0.81 | MAPT (0.69) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL2243980 | 0.80 | KMT2A (0.62) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL20762068 | 0.80 | MAPT (0.61) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL3400808 | 0.79 | SMN1; SMN2 (0.70) | MAPTKMT2APKMMEN1HPGD | |
| SCHEMBL12004226 | 0.79 | MAPT (0.56) | MAPTHCAR3KMT2APKMMEN1 | |
| SCHEMBL14402 | 0.79 | AKR1C3 (0.57) | MAPTHCAR3KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | MAPT 282/4885HCAR3 123/4885KMT2A 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.